Skip to main content

Table 3 Differences in EMB/INH/RIF resistance by age, race, and HIV status, by county DOT program type1

From: Does directly observed therapy (DOT) reduce drug resistant tuberculosis?

  Selective DOT county Universal DOT county     
  (n = 1207) (n = 514)     Interaction
Stratifying factor No. Resistant (%) No. Resistant (%) OR (95% CI) p-value p-value2
Age (yrs)         0.06
   <30 28 (9) 8 (7) 1.3 (0.5, 2.9) 0.58  
   30 - 59 59 (8) 15 (5) 1.7 (0.9, 3.1) 0.08  
   60+ 8 (5) 2 (2) 2.1 (0.4, 10.2) 0.36  
Race         0.11
   Black 41 (8) 6 (4) 2.1 (0.9, 5.1) 0.09  
   Hispanic 20 (6) 10 (8) 0.7 (0.3, 1.5) 0.34  
   White 8 (4) 3 (2) 1.4 (0.3, 5.6) 0.65  
   Asian/other 26 (18) 6 (8) 2.8 (1.1, 7.1) 0.03  
HIV status         0.52
   Negative 74 (7) 20 (4) 1.6 (1.0, 2.7) 0.07  
   Positive 21 (11) 5 (8) 1.2 (0.4, 3.6) 0.68  
  1. 1Separate analyses were done for each level of each stratifying factor; e.g., among patients aged <30, 28 (9%) patients from selective DOT and 8 (7%) from universal DOT were resistant, with an OR of 1.3 associating increased resistance with selective DOT. Analyses were adjusted for age, race, and/or HIV status, as appropriate, depending on the stratification factor.
  2. 2Interaction between DOT program and the stratifying factor.